Should hemoglobin be normalized in patients with chronic kidney disease?

Seminars in Dialysis

Volumn 15, Issue 1, 2002, Pages 8-13

  Stevens, Lesley ^a   Stigant, Caroline ^b   Levin, Adeera ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ANEMIA; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COGNITION; EXERCISE TOLERANCE; HUMAN; QUALITY OF LIFE; REFERENCE VALUE; RENAL REPLACEMENT THERAPY; REVIEW;

ANEMIA; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; COGNITION; EXERCISE TOLERANCE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; REFERENCE VALUES; RENAL DIALYSIS;

EID: 0036370781     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-139x.2002.00004.x     Document Type: Review

References (37)

1. Collins AJ, Ma JZ, Xia A, Ebben J: Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 32(6 suppl 4):S133-S141, 1998
2. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 28:53-61, 1996
3. Harnett JD, Kent GM, Foley RN, Parfrey PS: Cardiac function and hematocrit level. Am J Kidney Dis 25(4 suppl 1):S3-S7, 1995
4. Madore F, Lowrie E, Brugnara C, Lew N, Lazarus M, Bridges K, Owen W: Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 8:1921-1929, 1997
5. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. BMJ 300:573-578, 1990
6. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
7. Evans RW, Radar B, Manninen DL, Cooperative Multicenter EPO Clinical Trial Group: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263:825-830, 1990
8. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325-1335, 2000
9. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M: Cardiovascular effects of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:250-256, 2000
10. Marsh JT, Brown WS, Wolcott D, Carr CR, Harper R, Schweitzer SV, Nissenson AR: RHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 39:155-163, 1991
11. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ: Effects of hemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15:1425-1430, 2000
12. Nisensson AR, Pickett JL, Theberge DC, Brown WS, Schweitzer SU: Brain function is better in hemodialysis patients when hematocrit is normalized with erythropoietin [abstract]. J Am Soc Nephrol 7:1459, 1996
13. Collins A, Ebben J, Ma J: Frequent IV iron dosing is associated with higher infectious deaths [abstract]. J Am Soc Nephrol 8:190A, 1997
14. Hoen B, Kessler M, Hestin D, Mayeux D: Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 10:377-381, 1995
15. Tielemans CL, Lenclud CM, Wens R, Collart FE, Dratwa M: Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections: beneficial effects of desferrioxamine. Nephrol Dial Transplant 4:883-887, 1989
16. Benz RL, Pressman MR, Hovick ET, Peterson DD: A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (the SLEEPO study). Am J Kidney Dis 34:1089-1095, 1999
17. Nissenson AR: Optimal hematocrit in patients on dialysis therapy. Am J Kidney Dis 32(suppl 4):S142-S146, 1998
18. Stivelman JC: Benefits of anaemia treatment on cognitive function. Nephrol Dial Transplant 15(suppl 3):29-35, 2000
19. Horina JH, Schwaberger G, Brussee H, Sauseng-Fellegger G, Holzer H, Krejs GJ: Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin. Nephrol Dial Transplant 8:1219-1222, 1993
20. O'Sullivan DA, McCarthy JT, Kumar R, Williams AW: Improved biochemical variables, nutrient intake, and hormonal factors in slow nocturnal hemodialysis: a pilot study. Mayo Clin Proc 73:1123-1124, 1998
21. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
22. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34:125-134, 1999
23. Franch HA, Mitch WE: Catabolism in uremia: the impact of metabolic acidosis. J Am Soc Nephrol 9(suppl 12):S78-S81, 1998
24. Raine AEG, Seymour AML, Robert AFC, Radda GK, Ledingham JGG: Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 92:2934-2940, 1993
25. Matthais S, Honack C, Rosen P, Zebe H, Ritz E: Glucose uptake and expression of glucose transporters in the heart of uremic rats [abstract]. J Am Soc Nephrol 6:1023, 1995
26. Metivier F, Marchais SJ, Guerein AP, Pannier B, London GM: Pathophysiology of anemia: focus on the heart and blood vessels. Nephrol Dial Transplant 15(suppl 3):14-18, 2000
27. Bonilla S, Goercke IA, Bozzo S, Alvo M, Michea L, Marusic ET: Effect of chronic renal failure on Na,K-ATPase alpha 1 and alpha 2 mRNA transcription in rat skeletal muscle. J Clin Invest 29:39-43, 1991
28. Digicaylioglu M, Lipton SA: Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappa B signaling cascades. Nature 412:641-647, 2001
29. Brines ML, Ghezzi P, Keenan S, de Agnello D, Lanerolle NC, Cerami C, Itri LM, Cerami A: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97:10526-10531, 2000
30. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37:1775-1780, 2001
31. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29:541-548, 1997
32. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, Taylor DW: Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 4:1809-1810, 1994
33. Martino MA, Vogel KM, O'Brien SP, Kerstein MD: Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis. J Am Coll Surg 187:616-619, 1998
34. Besarab A, Medina F, Musial E, Picarello N, Michael H: Recombinant human erythropoietin does not increase clotting in vascular accesses. ASAIO Trans 36:M749-M753, 1990
35. Stefanidis I, Mertens PR, Wurth P, Bach R, Makropoulos W, Mann H, Heintz B: Influence of recombinant human erythropoietin therapy on plasma endothelin-1 levels during hemodialysis. Int J Artif Organs 24:367-373, 2001
36. Vaziri ND: Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens 10:633-637, 2001
37. Tsao CJ, Kao RH, Cheng TY, Huang CC, Chang SL, Lee FN. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients. Int J Hematol 55:197-203, 1992